Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Xcell Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
AmplifyBio And Xcell Partner To Manufacture TCR-T Cell Therapy
Details : The partnership aims to focus on TCR therapy and work through process development, preclinical analysis, and first-in-human trials using Xcellbio’s AVATAR Foundry platform for solid tumors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Xcell Biosciences
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Xcell Biosciences
Deal Size : Undisclosed
Deal Type : Expanded Collaboration
Xcell Biosciences Expands AmplifyBio Partnership For Cell and Gene Therapies
Details : The collaboration aims to identify key elements for successful manufacture of TCR therapies. Experiments have progressed from in vitro to in vivo, to target human papillomavirus-positive tumors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 10, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Xcell Biosciences
Deal Size : Undisclosed
Deal Type : Expanded Collaboration